ClinicalTrials.gg
CompletedNCT03064126RANGER II SFAUpdated Oct 29, 2024Results posted

RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

A Phase 3 interventional study of RANGER™ Paclitaxel Coated Balloon and Paclitaxel in Peripheral Artery Disease, Atherosclerosis and Artery Diseases, Peripheral, sponsored by Boston Scientific Corporation. Completed at 67 sites in 6 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Boston Scientific Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
25th of 373
440 · median 64
Started
2017
with 37 others
Phase 3
31 of 479
8 open now
Registered
238th of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 25th largest by enrollment of the 373 interventional ones that give a count, is one of 38 that started in 2017, is one of 31 in phase 3, and was the 238th registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA).

Long Balloon substudy: To evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) Ranger™ Paclitaxel Coated Balloon in the 120, 150 and 200 mm lengths for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.

Read the detailed description

The RANGER II SFA is a global, prospective, multi-center clinical trial. Approximately 446 subjects will be enrolled at up to 80 study centers worldwide. Regions participating include the United States, Canada, European Union, Japan and New Zealand.

The trial consists of a single-blind, superiority, 3:1 (Ranger Drug-Coated Balloon (DCB) vs. Standard PTA) randomized controlled trial (RCT) and a concurrent, non-randomized, single-arm, pharmacokinetic (PK) substudy, and a concurrent, non-blinded, non-randomized, Long balloon substudy.

03

Conditions studied

  • Peripheral Artery Disease
  • Atherosclerosis
  • Artery Diseases, Peripheral
  • Plaque, Atherosclerotic
  • Occlusive Arterial Disease

Keywords

  • Artery
  • Atherosclerosis
  • Arterial
  • Peripheral
  • Plaque
  • Angioplasty
  • PTA
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject (or Legal Guardian) is willing and able to provide consent before any study-specific tests or procedures are performed and agree to attend all required follow-up visits;
  2. Subject at least 20 years of age;
  3. Chronic symptomatic lower limb ischemia defined as Rutherford classification 2, 3, or 4;
  4. Target lesion is in the native SFA and/or PPA down to the P1 segment;
  5. Patent popliteal and infrapopliteal arteries, i.e., single vessel runoff or better with at least one of three vessels patent (less than 50 % stenosis) to the ankle or foot;
  6. Reference vessel diameter ≥ 4 mm and ≤ 8 mm by visual estimate;
  7. Angiographic evidence that target lesion consists of a single de novo, non-stented and non-atherectomy treated or restenotic lesion (or tandem lesions or a combination lesion as defined below) that is:

    • ≥ 70%-99% stenotic with total lesion length up to 180 mm by visual estimate.
    • Occluded with total lesion length ≤ 100 mm by visual estimate.
    • If lesion is restenotic, most recent PTA treatment must be > 3 months prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. , documented in the Investigator's opinion, of less than 12 months;
  2. Hemorrhagic stroke or cardiac event (e.g. STEMI, unstable angina) within 6 months prior to enrollment;
  3. Known allergies or sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies, and/or paclitaxel;
  4. Known or to contrast dye that, in the opinion of the investigator, cannot be adequately pre-medicated;
  5. Chronic renal insufficiency with serum creatinine > 2.0 mg/dL within 30 days of index procedure or treatment with dialysis;
  6. count \< 80,000 mm 3 or > 600,000 mm 3 or history of bleeding diathesis;
  7. Receiving therapy;
  8. Septicemia at the time of enrollment;
  9. Any major intervention planned within 30 days post index procedure;
  10. Presence of other hemodynamically significant outflow lesions in the target limb requiring intervention within 30 days of enrollment;
  11. Failure to successfully cross the target lesion with a guidewire;
  12. Failure to successfully pre-dilate the target vessel;
  13. Patient has lesion that requires the use of adjunctive primary treatment modalities (i.e. laser, atherectomy, scoring/cutting balloon, other debulking devices, etc.) during the index procedure;
  14. History of major amputation in the target limb;
  15. Target lesion or vessel has ever been previously treated with stent (e.g. in-stent restenosis) or surgery. Target lesion or vessel has been treated with atherectomy or a DCB in the past 12 months;
  16. Pregnant or breast feeding;
  17. Presence of aneurysm in the target vessel;
  18. Acute ischemia and/or acute thrombosis of the SFA/PPA prior to enrollment;
  19. Patient has significant inflow disease which cannot be treated prior to the target lesion treatment;
  20. Patient has perforated targeted vessel as evidenced by extravasation of contrast media;
  21. Patient has severe calcification that renders the lesion undilatable;
  22. Current participation in another drug or device clinical trial that has not completed the primary endpoint at the time of randomization/enrollment or that clinically interferes with the current trial endpoints.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    RANGER™ Paclitaxel Coated Balloon

    RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.

    Device: RANGER™ Paclitaxel Coated Balloon · Drug: Paclitaxel

  • Active comparator
    Standard Balloon Angioplasty

    Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.

    Procedure: Standard Balloon Angioplasty

Interventions

  • DeviceRANGER™ Paclitaxel Coated Balloon

    A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a "balloon" at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.

    Also known as: Percutaneous Transluminal Angioplasty (PTA)

  • The RANGER™ Balloon is coated with the drug Paclitaxel.

  • ProcedureStandard Balloon Angioplasty

    A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a "balloon" at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.

    Also known as: Percutaneous Transluminal Angioplasty (PTA)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Primary Lesion Patency

    RCT outcome measure: Primary patency of the target lesion is determined by Peak Systolic Velocity Ratio (PSVR) ≤ 2.4 (by duplex ultrasound (DUS)) and freedom from clinically-driven Target Lesion Revascularization (TLR) within 12 months from procedure. Lesion patency is defined as freedom from more than 50% stenosis based on DUS PSVR comparing data within the treated segment to the proximal normal arterial segment. PSVR \>2.4 suggests \>50% stenosis. LB Substudy outcome measure: Primary patency of the target lesion is determined by duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≤ 2.4 in absence of clinically-driven TLR. Primary effectiveness endpoint is assessed at 6 months post-procedure. PK Substudy: There was no prespecified analysis of primary lesion patency.

    Time frame: 12 months (RCT); 6 months (LB substudy)

  2. Major Adverse Events (MAEs) (Primary Safety Endpoint)

    RCT: MAE is defined as a composite of freedom from all-cause death through 1 month, target limb major amputation (defined as at or above the ankle) within 12 months, and/or Target Lesion Revascularization (TLR) within 12 months. LB Substudy: Primary safety endpoint assesses the occurrence of MAE defined as all-cause death through 1 month, target limb major amputation and/or TLR at 6 and 12 months post-index procedure. PK Substudy: There was no prespecified analysis of primary safety endpoint.

    Time frame: Primary safety endpoint assessed at 12 months for RCT study and at both 6 and 12 months for LB substudy.

Secondary outcomes

  1. Number of Participants With Technical Success of Angioplasty Procedure

    Technical success defined as successful delivery, balloon inflation and deflation and retrieval of the intact trial device without burst below the rated burst pressure. RCT Standard Balloon Angioplasty: Device deficiency data is only collected for Ranger DCB; data not collected for Standard PTA group; there is no pre-specified analysis of this outcome for the Standard PTA group.

    Time frame: Day 0

  2. Number of Participants With Procedural Success of Angioplasty Procedure

    Procedural success defined as residual stenosis of less than or equal to 50% (non-stented subjects) or less than or equal to 30% (stented subjects) by core laboratory evaluation.

    Time frame: Day 0

  3. Number of Participants With Clinical Success Rate Assessment

    Clinical success defined as procedural success without procedural complications including death, major target limb amputation, thrombosis of the target lesion, or clinically-driven TLR prior to discharge.

    Time frame: Day 0

  4. Number of Major Adverse Event (MAE) Assessment

    MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 60-months in RCT. MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 12-months in LB substudy. PK Substudy: There was no prespecified analysis of MAEs for PK substudy.

    Time frame: 60-months (RCT); 12-months (LB substudy).

  5. Number of Clinical Events Committee (CEC) Adjudicated Events

    CEC adjudicated events including death of any cause, target lesion revascularization (TLR), target vessel revascularization (TVR) and target limb amputation (TLA). Denominators for the cumulative rate will be based on 1) subjects with events, and 2) subjects with no events but their follow-up time reaches (or is beyond) the earliest visit window. LB substudy follow-up through 12 month.

    Time frame: 1, 6, 12, 24, 36, 48 and 60 months (RCT and PK substudy); 1, 6 and 12 months (LB substudy)

  6. Number of Participants With Rate of Primary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline

    Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure without the need for repeat TLR. LB Substudy: Follow-up through 12-month. PK Substudy: There was no prespecified analysis of Rate of Primary Sustained Clinical Improvement for PK substudy.

    Time frame: 1, 6, 12, 24 and 36 months post-procedure (RCT); 1, 6 and 12 months post-procedure (LB substudy).

  7. Number of Participants With Rate of Secondary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline.

    Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure including those subjects with repeat TLR. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Secondary Sustained Clinical Improvement for PK substudy.

    Time frame: 1, 6, 12, 24 and 36 months post-procedure (RCT): 1, 6, and 12 months post-procedure (LB substudy)

  8. Number of Participants With Rate of Hemodynamic Improvement as Assessed by Changes in Ankle Brachial Index (ABI) From Baseline.

    Improvement of ABI by ≥ 0.1 or to an ABI ≥ 0.90 as compared to the pre-procedure value without the need for repeat revascularization. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Hemodynamic Improvement for PK substudy.

    Time frame: 1, 6, 12, 24, and 36 months post-procedure (RCT); 1, 6, and 12 months post-procedure (LB substudy)

  9. Walking Improvement (Distance) at 6 and 12 Months as Assessed by Change in Six Minute Walk Test (6MWT) From Baseline

    The 6MWT measure the maximal walking distance that a patient achieves on a flat, hard surface within a period of 6 minutes. It evaluates the global and integrated responses of all physiological systems involved during exercise including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, neuromuscular units and muscle metabolism. Change in distance walked from baseline to 12 months. LB Substudy: There was no prespecified analysis of Walking Improvement (distance) for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement (distance) for PK substudy.

    Time frame: 6 and 12 months post-procedure (RCT)

  10. Walking Improvement Assessed by Change in Walking Impairment Questionnaire (WIQ) From Baseline.

    The WIQ is a functional assessment questionnaire that evaluates walking ability with regard to speed, distance and stair climbing ability. It also assesses the reasons that walking ability might be limited. Range of scores include 0% (worst score) to 100% (best score). Walking improvement change assessed from baseline. LB Substudy: There was no prespecified analysis of Walking Improvement for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement for the PK substudy.

    Time frame: 1, 6, 12, 24 and 36 months post-procedure (RCT)

  11. Duplex-defined Binary Restenosis (PSVR > 2.4) of the Target Lesion

    Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, 12, 24 and 36 Months (RCT) Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, and 12 (LB Substudy) PK Substudy: There was no prespecified analysis of duplex defined binary restenosis of the target lesion

    Time frame: 1, 6, 12, 24, and 36-months post-procedure (RCT); 1, 6, and 12-months post-procedure (LB substudy)

  12. Patient Utility Values as Assessed by Change in EQ-5D From Baseline.

    Patient Utility Values as assessed by change in EQ-5D from baseline at 1, 6, 12, 24 and 36-months post-procedure. The EuroQOL (EQ)-5D is a multi-attribute health classification system. The EQ-5D uses a 5-dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) descriptive system, which each consisting of 5 response options (no problems, slight problems, moderate problems, severe problems, or extreme problems/inability to perform). Outcomes reported as "Improvement" defined as improving at least one category from baseline. LB Substudy: There was no prespecified analysis of Patient Utility Values for the LB Substudy. PK Substudy: There was no prespecified analysis of Patient Utility Values for the PK Substudy.

    Time frame: 1, 6, 12, 24 and 36-months post-procedure (RCT).

  13. Changes in Healthcare Utilization Over Time

    Changes in healthcare utilization over time as measured by hospitalization readmission. Readmission Rate represents (# of subjects/Total enrolled subjects) who were hospitalized due to TLR/TVR or due to Procedure/Device related AE. LB Substudy: Follow-up through 12 Month. PK Substudy: There was no prespecified analysis of healthcare utilization over time for the PK Substudy.

    Time frame: 1, 6, 12, 24, 36, 48 and 60-months post-procedure (RCT); 1, 6, 12-months post-procedure (LB substudy)

  14. PK Parameters Paclitaxel (PTx) Dose

    Summary of Pharmacokinetic Parameters in PK substudy. Paclitaxel (PTx) Dose PK parameter data not collected or analyzed in RCT or LB substudy.

    Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.

  15. PK Parameters - Maximum Plasma Concentration

    Summary of Pharmacokinetic Parameters in PK substudy. cmax (ng/mL) = Maximum plasma concentration PK data not collected or analyzed in RCT or LB substudy.

    Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.

  16. PK Parameters - Tmax

    Summary of Pharmacokinetic Parameters in PK substudy. - Tmax Tmax (h) = The timepoint where cmax is reached PK parameter data not collected or analyzed in RCT or LB substudy.

    Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.

  17. PK Parameters - Area Under the Blood Concentration Versus Time Curve From Time Zero up to the Time of the Last Quantifiable Concentration, Calculated by Trapezoidal Methods.

    Summary of Pharmacokinetic Parameters in PK substudy. AUC0-t (ng\*h/mL) = Area under the blood concentration versus time curve from time zero up to the time of the last quantifiable concentration, calculated by trapezoidal methods. PK parameter data not collected or analyzed in RCT or LB substudy.

    Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.

07

Results

Posted Jul 15, 2020

Participant flow

Participant flow — Overall Study
MilestoneRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) Substudy
Started278985212
Completed20367488
Not completed753144
Withdrew: Death401642
Withdrew: Withdrawal by subject17902
Withdrew: Lost to follow-up7300
Withdrew: Adverse event2000
Withdrew: Physician decision3000
Withdrew: Other reason for early termination3200
Withdrew: Missed visit3100

Outcome measures

PrimaryNumber of Participants With Primary Lesion Patency

RCT outcome measure: Primary patency of the target lesion is determined by Peak Systolic Velocity Ratio (PSVR) ≤ 2.4 (by duplex ultrasound (DUS)) and freedom from clinically-driven Target Lesion Revascularization (TLR) within 12 months from procedure. Lesion patency is defined as freedom from more than 50% stenosis based on DUS PSVR comparing data within the treated segment to the proximal normal arterial segment. PSVR \>2.4 suggests \>50% stenosis. LB Substudy outcome measure: Primary patency of the target lesion is determined by duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≤ 2.4 in absence of clinically-driven TLR. Primary effectiveness endpoint is assessed at 6 months post-procedure. PK Substudy: There was no prespecified analysis of primary lesion patency.

Time frame:
12 months (RCT); 6 months (LB substudy)
Reported as:
Count of participants · Participants
Number of Participants With Primary Lesion Patency
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
Number of Participants With Primary Lesion Patency1945743
Statistical analysis
  • RANGER™ Paclitaxel Coated Balloon RCT vs Standard Balloon Angioplasty RCT · Chi-squared · p = 0.0017 · Risk difference (rd): 0.166
PrimaryMajor Adverse Events (MAEs) (Primary Safety Endpoint)

RCT: MAE is defined as a composite of freedom from all-cause death through 1 month, target limb major amputation (defined as at or above the ankle) within 12 months, and/or Target Lesion Revascularization (TLR) within 12 months. LB Substudy: Primary safety endpoint assesses the occurrence of MAE defined as all-cause death through 1 month, target limb major amputation and/or TLR at 6 and 12 months post-index procedure. PK Substudy: There was no prespecified analysis of primary safety endpoint.

Time frame:
Primary safety endpoint assessed at 12 months for RCT study and at both 6 and 12 months for LB substudy.
Reported as:
Count of participants · Participants
Major Adverse Events (MAEs) (Primary Safety Endpoint)
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
6 Month Primary Safety Endpoint——50
12 Month Primary Safety Endpoint2417647
Statistical analysis
  • RANGER™ Paclitaxel Coated Balloon RCT vs Standard Balloon Angioplasty RCT · Chi-squared · p = <0.0001 · Risk difference (rd): 0.106
SecondaryNumber of Participants With Technical Success of Angioplasty Procedure

Technical success defined as successful delivery, balloon inflation and deflation and retrieval of the intact trial device without burst below the rated burst pressure. RCT Standard Balloon Angioplasty: Device deficiency data is only collected for Ranger DCB; data not collected for Standard PTA group; there is no pre-specified analysis of this outcome for the Standard PTA group.

Time frame:
Day 0
Reported as:
Count of participants · Participants
Number of Participants With Technical Success of Angioplasty Procedure
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) Substudy
Number of Participants With Technical Success of Angioplasty Procedure277—4712
SecondaryNumber of Participants With Procedural Success of Angioplasty Procedure

Procedural success defined as residual stenosis of less than or equal to 50% (non-stented subjects) or less than or equal to 30% (stented subjects) by core laboratory evaluation.

Time frame:
Day 0
Reported as:
Count of participants · Participants
Number of Participants With Procedural Success of Angioplasty Procedure
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) Substudy
Number of Participants With Procedural Success of Angioplasty Procedure269974912
SecondaryNumber of Participants With Clinical Success Rate Assessment

Clinical success defined as procedural success without procedural complications including death, major target limb amputation, thrombosis of the target lesion, or clinically-driven TLR prior to discharge.

Time frame:
Day 0
Reported as:
Count of participants · Participants
Number of Participants With Clinical Success Rate Assessment
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) Substudy
Number of Participants With Clinical Success Rate Assessment267964811
SecondaryNumber of Major Adverse Event (MAE) Assessment

MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 60-months in RCT. MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 12-months in LB substudy. PK Substudy: There was no prespecified analysis of MAEs for PK substudy.

Time frame:
60-months (RCT); 12-months (LB substudy).
Reported as:
Count of participants · Participants
Number of Major Adverse Event (MAE) Assessment
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
12-Month MAE (Composite Endpoint)15153
12-Month All Causes of Death at 1-Month100
12-Month Target Limb Major Amputation000
12-Month Target Lesion Revascularization14153
60-Month MAE (Composite Endpoint)5723—
60-Month All Causes of Death at 1-Month10—
60-Month Target Limb Major Amputation10—
60-Month Target Lesion Revascularization5623—
SecondaryNumber of Clinical Events Committee (CEC) Adjudicated Events

CEC adjudicated events including death of any cause, target lesion revascularization (TLR), target vessel revascularization (TVR) and target limb amputation (TLA). Denominators for the cumulative rate will be based on 1) subjects with events, and 2) subjects with no events but their follow-up time reaches (or is beyond) the earliest visit window. LB substudy follow-up through 12 month.

Time frame:
1, 6, 12, 24, 36, 48 and 60 months (RCT and PK substudy); 1, 6 and 12 months (LB substudy)
Reported as:
Number · Participants
Number of Clinical Events Committee (CEC) Adjudicated Events
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) Substudy
1-Month All Deaths1000
1-Month All Target Lesion Revascularization (TLR)0010
1-Month All Target Vessel Revascularization (TVR)0010
1-Month All Target Limb Amputation0000
6-Month All Deaths3221
6-Month All Target Lesion Revascularization (TLR)2310
6-Month All Target Vessel Revascularization (TVR)3310
6-Month All Target Limb Amputation1000
12- Month All Deaths5231
12-Month All Target Lesion Revascularization (TLR)141532
12-Month All Target Vessel Revascularization (TVR)161533
12-Month All Target Limb Amputation1001
24-Month All Deaths143—1
24-Month All Target Lesion Revascularization (TLR)3219—3
24-Month All Target Vessel Revascularization (TVR)3820—4
24-Month All Target Limb Amputation11—1
36-Month All Deaths295—1
36-Month All Target Lesion Revascularization (TLR)4221—3
36-Month All Target Vessel Revascularization (TVR)4923—4
36-Month All Target Limb Amputation13—1
48-Month All Deaths3610—2
48-Month All Target Lesion Revascularization (TLR)5223—3
48-Month All Target Vessel Revascularization (TVR)6026—4
48-Month All Target Limb Amputation23—1
60-Month All Deaths4016—2
60-Month All Target Lesion Revascularization (TLR)5623—3
60-Month All Target Vessel Revascularization (TVR)6426—4
60-Month All Target Limb Amputation33—1
SecondaryNumber of Participants With Rate of Primary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline

Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure without the need for repeat TLR. LB Substudy: Follow-up through 12-month. PK Substudy: There was no prespecified analysis of Rate of Primary Sustained Clinical Improvement for PK substudy.

Time frame:
1, 6, 12, 24 and 36 months post-procedure (RCT); 1, 6 and 12 months post-procedure (LB substudy).
Reported as:
Count of participants · Participants
Number of Participants With Rate of Primary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
1-Month Primary Sustained Clinical Improvement2569150
6-Month Primary Sustained Clinical Improvement2498348
12-Month Primary Sustained Clinical Improvement2226945
24-Month Primary Sustained Clinical Improvement18059—
36-Month Primary Sustained Clinical Improvement15053—
SecondaryNumber of Participants With Rate of Secondary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline.

Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure including those subjects with repeat TLR. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Secondary Sustained Clinical Improvement for PK substudy.

Time frame:
1, 6, 12, 24 and 36 months post-procedure (RCT): 1, 6, and 12 months post-procedure (LB substudy)
Reported as:
Count of participants · Participants
Number of Participants With Rate of Secondary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline.
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
1-Month Secondary Sustained Clinical Improvement2569151
6-Month Secondary Sustained Clinical Improvement2518548
12-Month Secondary Sustained Clinical Improvement2308147
24-Month Secondary Sustained Clinical Improvement20573—
36-Month Secondary Sustained Clinical Improvement17667—
SecondaryNumber of Participants With Rate of Hemodynamic Improvement as Assessed by Changes in Ankle Brachial Index (ABI) From Baseline.

Improvement of ABI by ≥ 0.1 or to an ABI ≥ 0.90 as compared to the pre-procedure value without the need for repeat revascularization. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Hemodynamic Improvement for PK substudy.

Time frame:
1, 6, 12, 24, and 36 months post-procedure (RCT); 1, 6, and 12 months post-procedure (LB substudy)
Reported as:
Count of participants · Participants
Number of Participants With Rate of Hemodynamic Improvement as Assessed by Changes in Ankle Brachial Index (ABI) From Baseline.
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
1-Month Hemodynamic Improvement2528343
6-Month Hemodynamic Improvement2306643
12-Month Hemodynamic Improvement2025740
24-Month Hemodynamic Improvement16647—
36-Month Hemodynamic Improvement12845—
SecondaryWalking Improvement (Distance) at 6 and 12 Months as Assessed by Change in Six Minute Walk Test (6MWT) From Baseline

The 6MWT measure the maximal walking distance that a patient achieves on a flat, hard surface within a period of 6 minutes. It evaluates the global and integrated responses of all physiological systems involved during exercise including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, neuromuscular units and muscle metabolism. Change in distance walked from baseline to 12 months. LB Substudy: There was no prespecified analysis of Walking Improvement (distance) for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement (distance) for PK substudy.

Time frame:
6 and 12 months post-procedure (RCT)
Reported as:
Mean · Meters
Walking Improvement (Distance) at 6 and 12 Months as Assessed by Change in Six Minute Walk Test (6MWT) From Baseline
MetersRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCT
6-Month Walking Improvement (Distance)40.7 ± 179.055.9 ± 117.5
12-Month Walking Improvement (Distance)36.3 ± 162.246.1 ± 115.4
SecondaryWalking Improvement Assessed by Change in Walking Impairment Questionnaire (WIQ) From Baseline.

The WIQ is a functional assessment questionnaire that evaluates walking ability with regard to speed, distance and stair climbing ability. It also assesses the reasons that walking ability might be limited. Range of scores include 0% (worst score) to 100% (best score). Walking improvement change assessed from baseline. LB Substudy: There was no prespecified analysis of Walking Improvement for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement for the PK substudy.

Time frame:
1, 6, 12, 24 and 36 months post-procedure (RCT)
Reported as:
Mean · Percentage increase
Walking Improvement Assessed by Change in Walking Impairment Questionnaire (WIQ) From Baseline.
Percentage increaseRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCT
1-Month Walking Improvement Scoring Summary33.61 ± 35.7834.47 ± 35.20
6-Month Walking Improvement Scoring Summary32.25 ± 37.0732.25 ± 37.07
12-Month Walking Improvement Scoring Summary32.06 ± 39.4934.72 ± 36.85
24-Month Walking Improvement Scoring Summary29.50 ± 36.8729.76 ± 41.88
36-Month Walking Improvement30.37 ± 38.8534.93 ± 39.03
SecondaryDuplex-defined Binary Restenosis (PSVR > 2.4) of the Target Lesion

Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, 12, 24 and 36 Months (RCT) Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, and 12 (LB Substudy) PK Substudy: There was no prespecified analysis of duplex defined binary restenosis of the target lesion

Time frame:
1, 6, 12, 24, and 36-months post-procedure (RCT); 1, 6, and 12-months post-procedure (LB substudy)
Reported as:
Count of participants · Participants
Duplex-defined Binary Restenosis (PSVR > 2.4) of the Target Lesion
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
1-month PSVR > 2.4703
6-month PSVR > 2.48122
12-month PSVR > 2.42183
24-month PSVR > 2.4176—
36-month PSVR > 2.4175—
SecondaryPatient Utility Values as Assessed by Change in EQ-5D From Baseline.

Patient Utility Values as assessed by change in EQ-5D from baseline at 1, 6, 12, 24 and 36-months post-procedure. The EuroQOL (EQ)-5D is a multi-attribute health classification system. The EQ-5D uses a 5-dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) descriptive system, which each consisting of 5 response options (no problems, slight problems, moderate problems, severe problems, or extreme problems/inability to perform). Outcomes reported as "Improvement" defined as improving at least one category from baseline. LB Substudy: There was no prespecified analysis of Patient Utility Values for the LB Substudy. PK Substudy: There was no prespecified analysis of Patient Utility Values for the PK Substudy.

Time frame:
1, 6, 12, 24 and 36-months post-procedure (RCT).
Reported as:
Count of participants · Participants
Patient Utility Values as Assessed by Change in EQ-5D From Baseline.
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCT
1-Month Mobility Improvement14952
1-Month Self-Care Improvement2412
1-Month Usual Activities Improvement10744
1-Month Pain/Discomfort Improvement14161
1-Month Anxiety/Depression Improvement5523
6-Months Mobility Improvement14945
6-Month Self-Care Improvement2710
6-Month Usual Activities Improvement10238
6-Month Pain/Discomfort Improvement12647
6-Month Anxiety/Depression Improvement6124
12-Months Mobility Improvement14048
12-Month Self-Care Improvement2614
12-Month Usual Activities Improvement9441
12-Month Pain/Discomfort Improvement13251
12-Month Anxiety/Depression Improvement5922
24-Months Mobility Improvement10942
24-Month Self-Care Improvement1712
24-Month Usual Activities Improvement8738
24-Month Pain/Discomfort Improvement10848
24-Month Anxiety/Depression Improvement4717
36-Months Mobility Improvement10037
36-Month Self-Care Improvement178
36-Month Usual Activities Improvement8032
36-Month Pain/Discomfort Improvement9638
36-Month Anxiety/Depression Improvement5416
SecondaryChanges in Healthcare Utilization Over Time

Changes in healthcare utilization over time as measured by hospitalization readmission. Readmission Rate represents (# of subjects/Total enrolled subjects) who were hospitalized due to TLR/TVR or due to Procedure/Device related AE. LB Substudy: Follow-up through 12 Month. PK Substudy: There was no prespecified analysis of healthcare utilization over time for the PK Substudy.

Time frame:
1, 6, 12, 24, 36, 48 and 60-months post-procedure (RCT); 1, 6, 12-months post-procedure (LB substudy)
Reported as:
Count of participants · Participants
Changes in Healthcare Utilization Over Time
ParticipantsRANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) Substudy
1-Month Readmission Rate641
6-month Readmission Rate851
12-Month Readmission Rate1893
24-Month Readmission Rate2813—
36-month Readmission Rate3315—
48-Month Readmission Rate3716—
60-Month Readmission Rate4116—
SecondaryPK Parameters Paclitaxel (PTx) Dose

Summary of Pharmacokinetic Parameters in PK substudy. Paclitaxel (PTx) Dose PK parameter data not collected or analyzed in RCT or LB substudy.

Time frame:
Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
Reported as:
Mean · μg
PK Parameters Paclitaxel (PTx) Dose
μgPharmacokinetics (PK) Substudy
PK Parameters Paclitaxel (PTx) Dose6136.6 ± 2554.3
SecondaryPK Parameters - Maximum Plasma Concentration

Summary of Pharmacokinetic Parameters in PK substudy. cmax (ng/mL) = Maximum plasma concentration PK data not collected or analyzed in RCT or LB substudy.

Time frame:
Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
Reported as:
Mean · ng/mL
PK Parameters - Maximum Plasma Concentration
ng/mLPharmacokinetics (PK) Substudy
PK Parameters - Maximum Plasma Concentration2.50 ± 2.17
SecondaryPK Parameters - Tmax

Summary of Pharmacokinetic Parameters in PK substudy. - Tmax Tmax (h) = The timepoint where cmax is reached PK parameter data not collected or analyzed in RCT or LB substudy.

Time frame:
Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
Reported as:
Mean · hours (h)
PK Parameters - Tmax
hours (h)Pharmacokinetics (PK) Substudy
PK Parameters - Tmax0.17 ± 0
SecondaryPK Parameters - Area Under the Blood Concentration Versus Time Curve From Time Zero up to the Time of the Last Quantifiable Concentration, Calculated by Trapezoidal Methods.

Summary of Pharmacokinetic Parameters in PK substudy. AUC0-t (ng\*h/mL) = Area under the blood concentration versus time curve from time zero up to the time of the last quantifiable concentration, calculated by trapezoidal methods. PK parameter data not collected or analyzed in RCT or LB substudy.

Time frame:
Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
Reported as:
Mean · ng*h/mL
PK Parameters - Area Under the Blood Concentration Versus Time Curve From Time Zero up to the Time of the Last Quantifiable Concentration, Calculated by Trapezoidal Methods.
ng*h/mLPharmacokinetics (PK) Substudy
PK Parameters - Area Under the Blood Concentration Versus Time Curve From Time Zero up to the Time of the Last Quantifiable Concentration, Calculated by Trapezoidal Methods.0.86 ± 0.76

Adverse events

Collected over Adverse event data collected through five-year (60-month) post-index procedure in RCT and PK substudy. Adverse event data collected through 12-month post index procedure in LB substudy All-Cause crude mortality includes deaths confirmed through survival status assessments.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RANGER™ Paclitaxel Coated Balloon44/278 (15.8%)212/278 (76.3%)176/278 (63.3%)
Standard Balloon Angioplasty20/98 (20.4%)73/98 (74.5%)63/98 (64.3%)
Long Balloon (LB) Substudy2/52 (3.8%)23/52 (44.2%)26/52 (50%)
Pharmacokinetics (PK) Substudy3/12 (25%)10/12 (83.3%)9/12 (75%)
Most frequent serious events
Showing 10 of 343
Most frequent serious events
EventRANGER™ Paclitaxel Coated BalloonStandard Balloon AngioplastyLong Balloon (LB) SubstudyPharmacokinetics (PK) Substudy
AnaemiaBlood and lymphatic system disorders5/2781/980/523/12
PneumoniaInfections and infestations15/2789/984/523/12
Peripheral artery stenosisVascular disorders63/27818/987/520/12
Coronary artery diseaseCardiac disorders12/2784/981/522/12
Oedema peripheralGeneral disorders1/2780/980/522/12
Acute kidney injuryRenal and urinary disorders11/2784/980/522/12
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/2781/980/522/12
Hypertensive crisisVascular disorders1/2781/980/522/12
Peripheral arterial occlusive diseaseVascular disorders14/2788/980/522/12
HypertensionVascular disorders1/2780/980/522/12
Most frequent other events
Showing 10 of 274
Most frequent other events
EventRANGER™ Paclitaxel Coated BalloonStandard Balloon AngioplastyLong Balloon (LB) SubstudyPharmacokinetics (PK) Substudy
Back painMusculoskeletal and connective tissue disorders9/2784/982/524/12
ConstipationGastrointestinal disorders2/2782/980/522/12
Peripheral artery stenosisVascular disorders17/2786/986/522/12
RhabdomyolysisMusculoskeletal and connective tissue disorders0/2780/980/522/12
Intermittent claudicationVascular disorders31/27811/982/521/12
Atrial fibrillationCardiac disorders3/2780/980/521/12
TinnitusEar and labyrinth disorders1/2780/980/521/12
Catheter site haematomaGeneral disorders1/2782/981/521/12
OedemaGeneral disorders0/2781/980/521/12
CellulitisInfections and infestations5/2782/980/521/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
Mean70.6 ± 9.569.1 ± 10.370.3 ± 9.963.3 ± 13.370.06 ± 9.87
Sex: Female, Male
Sex: Female, Male(Participants)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
Female10531148158
Male17367384282
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
Hispanic or Latino2180029
Caucasian15559519274
Asian (Japanese)772500102
Black, or African Heritage2041328
Native Hawaiian or other Pacific Islander00000
American Indian or Alaska Native10001
Other10001
Not Disclosed32005
Region of Enrollment
Region of Enrollment(participants)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
New Zealand722011
Canada1240016
Europe29850087
Japan772500102
United States15359012224
History of Smoking (Current)
History of Smoking (Current)(Participants)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
Count of participants8745246162
History of Smoking (Previous)
History of Smoking (Previous)(Participants)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
Count of participants15038235216
History of Smoking (Never)
History of Smoking (Never)(Participants)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
Count of participants40155161
History of Smoking (Unknown)
History of Smoking (Unknown)(Participants)RANGER™ Paclitaxel Coated Balloon RCTStandard Balloon Angioplasty RCTLong Balloon (LB) SubstudyPharmacokinetics (PK) SubstudyTotal
Count of participants10001

21 further baseline measures are reported on the registry.

08

Study locations

67 sites
  • Thomas Hospital
    Fairhope, Alabama 36532, United States
  • Rocky Mountain Regional VA Medical Center
    Aurora, Colorado 80045, United States
  • The Vascular Experts
    Stratford, Connecticut 06612, United States
  • Christiana Hospital
    Newark, Delaware 19718, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • South Florida Vascular Associates
    Coconut Creek, Florida 33073, United States
  • North Florida Regional Medical Center
    Gainesville, Florida 32605, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • AdventHealth Sebring
    Sebring, Florida 33872, United States
  • Wellstar Hospitals
    Marietta, Georgia 30060, United States
  • Kaiser Foundation Hospitals
    Honolulu, Hawaii 96819, United States
  • St. Joseph Hospital
    Fort Wayne, Indiana 46802, United States
  • Community Hospital
    Munster, Indiana 46321, United States
  • King's Daughters Medical Center - Kentucky Heart Institute
    Ashland, Kentucky 41101, United States
  • Terrebonne General Medical Center
    Houma, Louisiana 70360, United States
  • Mercy Hospital
    Coon Rapids, Minnesota 55433, United States
  • United Heart and Vascular Clinic
    Saint Paul, Minnesota 55102, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Staten Island University Hospital
    Staten Island, New York 10305, United States
  • Rex Hospital
    Raleigh, North Carolina 27607, United States
  • Coastal Carolina Surgical Associates
    Wilmington, North Carolina 28401, United States
  • Bethesda North Hospital
    Cincinnati, Ohio 45220, United States
  • Ohio State University Medical Center
    Columbus, Ohio 20161, United States
  • Premier Cardiovascular Institute
    Dayton, Ohio 45406, United States
  • Northeast Ohio Vascular Associates, Inc.
    Willoughby, Ohio 44094, United States
  • St. Charles Medical Center
    Bend, Oregon 97701, United States
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
  • University Medical Center-Greenville Memorial Hospital
    Greenville, South Carolina 29605, United States
  • Turkey Creek Medical Center
    Knoxville, Tennessee 37934, United States
  • North Park Heart & Vascular Center
    Dallas, Texas 75321, United States
  • Cardiology Clinic of San Antonio
    Live Oak, Texas 78233, United States
  • Texas Tech University Health Sciences Center
    Lubbock, Texas 79430, United States
  • North Dallas Research Associates
    McKinney, Texas 75069, United States
  • The Heart Hospital Baylor Plano
    Plano, Texas 75093, United States
  • THR Presbyterian Plano
    Plano, Texas 75093, United States
  • Tyler Cardiac and Endovascular Center
    Tyler, Texas 75701, United States
  • Davis Hospital and Medical Center
    Layton, Utah 84041, United States
  • West Virginia University Hospitals
    Morgantown, West Virginia 26506, United States
  • Aspirus Heart and Vascular Institute
    Wausau, Wisconsin 54401, United States
  • Medizinische Univ.-Kliniken Graz
    Graz, 8036, Austria
  • Allgemeines Krankenhaus AKH
    Vienna, 1090, Austria
  • Hanusch-Krankenhaus
    Vienna, 1140, Austria
  • Ziekenhuis Oost Limburg
    Genk, 3600, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Regionaal Ziekenhuis Heilig Hart Tienen
    Tienen, 3300, Belgium
  • Peter Lougheed Centre
    Calgary, Alberta T1Y 6J4, Canada
  • Hamilton General Hospital
    Hamilton, Ontario L8L 2X2, Canada
  • Fleurimont Hospital
    Sherbrooke, Quebec J1H 5N4, Canada
  • Hopital Saint - Francois d'Assise
    Quebec, G1L 3L2, Canada
  • Kokura Memorial Hospital
    Kitakyushu, Fukuoka, Japan
  • Iwaki City Medical Center
    Iwaki, Fukushima, Japan
  • Tokeidai Memorial Hospital
    Sapporo, Hokkaido, Japan
  • Kansai Rosai Hospital
    Amagasaki, Hyogo-ken, Japan
  • Saiseikai Yokohama-City Eastern Hospital
    Yokohama, Kanagawa, Japan
  • Sendai Kousei Hospital
    Sendai, Miyagi, Japan
  • Kishiwada Tokushukai Hospital
    Kishiwada, Osaka, Japan
  • Kasukabe Chuo General Hospital
    Kasukabe, Saitama, Japan
  • Saiseikai Central Hospital
    Minato, Tokyo, Japan
  • Kyoto Katsura Hospital
    Kyoto, Japan
  • Morinomiya Hospital
    Osaka, Japan
  • Osaka Saiseikai Nakatsu Hospital
    Osaka, Japan
  • Auckland City Hospital
    Auckland, 1010, New Zealand
  • Clinical Trials NZ
    Hamilton, 3204, New Zealand
  • Middlemore Hospital
    Otahuhu, 1640, New Zealand
09

References and documents

Publications

  • Litsky J, Chanda A, Stilp E, Lansky A, Mena C. Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery - focus on the paclitaxel eluting stent. Med Devices (Auckl). 2014 May 28;7:149-56. doi: 10.2147/MDER.S45472. eCollection 2014. PubMed 24920940 ↗
  • Kakkar AM, Abbott JD. Percutaneous versus surgical management of lower extremity peripheral artery disease. Curr Atheroscler Rep. 2015;17(2):479. doi: 10.1007/s11883-014-0479-0. PubMed 25612856 ↗
  • Razavi MK, Mustapha JA, Miller LE. Contemporary systematic review and meta-analysis of early outcomes with percutaneous treatment for infrapopliteal atherosclerotic disease. J Vasc Interv Radiol. 2014 Oct;25(10):1489-96, 1496.e1-3. doi: 10.1016/j.jvir.2014.06.018. Epub 2014 Aug 15. PubMed 25130307 ↗
  • Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010 Jun 1;3(3):267-76. doi: 10.1161/CIRCINTERVENTIONS.109.903468. Epub 2010 May 18. PubMed 20484101 ↗
  • Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014 Jan;7(1):10-9. doi: 10.1016/j.jcin.2013.05.022. PubMed 24456716 ↗
  • Schroe H, Sachar R, Keirse K, Soga Y, Brodmann M, Rao V, Werner M, Holden A, Lopez L, Krishnan P, Diaz-Cartelle J. The RANGER II superficial femoral artery trial: 1-year results of the long lesion cohort. Vasc Med. 2022 Oct;27(5):457-465. doi: 10.1177/1358863X221097164. Epub 2022 Aug 9. PubMed 35943120 ↗
  • Soga Y, Fujihara M, Yamamoto Y, Nakamura S, Iida O, Kawasaki D, Urasawa K, Ando H, Mori S, Suzuki K, Horie K, Diaz-Cartelle J, Kozuki A. One-year results for Japanese patients in RANGER II SFA. Heart Vessels. 2022 Apr;37(4):568-573. doi: 10.1007/s00380-021-01947-3. Epub 2021 Sep 23. PubMed 34557931 ↗
  • Sachar R, Soga Y, Ansari MM, Kozuki A, Lopez L, Brodmann M, Schroe H, Ramanath VS, Diaz-Cartelle J, Zeller T; RANGER II SFA Investigators. 1-Year Results From the RANGER II SFA Randomized Trial of the Ranger Drug-Coated Balloon. JACC Cardiovasc Interv. 2021 May 24;14(10):1123-1133. doi: 10.1016/j.jcin.2021.03.021. PubMed 34016410 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Nov 2019, 32 months.

Results were first posted in Jul 2020, 7 months after primary completion.

Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2017
First posted
Feb 24, 2017
StartActual
Mar 2, 2017
Primary completionActual
Nov 18, 2019
CompletionActual
Oct 25, 2023
Results first posted
Jul 15, 2020
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03064126
Responsible party
Sponsor
First posted
Feb 24, 2017
Start date
Mar 2, 2017
Primary completion
Nov 18, 2019
Completion
Oct 25, 2023
Results posted
Jul 15, 2020
Last update
Oct 29, 2024

Study contacts

Thomas Zeller, MD
principal investigator · Universitaets-Herzzentrum
Ravish Sachar, MD
principal investigator · University of North Carolina - Rex Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion